Class: Potassium-sparing diuretic
- Capsules 50 mg
- Capsules 100 mg
Interferes with sodium reabsorption at distal renal tubule, resulting in increased excretion of sodium and water and decreased excretion of potassium.
C max is 30 ng/mL and T max is 3 h. Triamterene is rapidly absorbed; max effect is seen in several days.
Triamterene crosses the placental barrier.
Triamterene is primarily metabolized to sulfate conjugate of hydroxytriamterene.
Less than 50% of triamterene is excreted in urine.
Onset of action is 2 to 4 h after ingestion.
Time to peak effect is 3 h.
Duration of diuresis depends on several factors, especially renal function, but generally it tapers off 7 to 9 h after administration.
Indications and Usage
Treatment of edema associated with CHF, hepatic cirrhosis, and nephrotic syndrome; treatment of steroid-induced edema, idiopathic edema, and edema caused by secondary hyperaldosteronism; management of hypertension in patient with diuretic-induced hypokalemia or at risk of hypokalemia.
Treatment with spironolactone or amiloride; anuria; severe hepatic disease; hyperkalemia; severe or progressive kidney disease or dysfunction, with exception of nephrosis.
Dosage and AdministrationAdults
PO 100 mg twice daily after meals (max, 300 mg/day).Children
PO 2 to 4 mg/kg/day given in 1 dose or 2 divided doses (max, 300 mg/day).
Store at room temperature in tight, light resistant container.
Drug InteractionsACE inhibitors
May result in severely elevated serum potassium levels.Indomethacin
May cause rapid progression into acute renal failure.Potassium preparations and salt substitutes
May severely increase serum potassium levels, possibly resulting in cardiac arrhythmias or cardiac arrest. Do not take with potassium preparations.
Laboratory Test Interactions
May interfere with fluorometry such as quinidine serum levels and LDH determination.
Weakness; fatigue; dizziness; headache.
Diarrhea; nausea; vomiting; dry mouth.
Azotemia; elevated BUN and creatinine; renal stones; bluish discoloration to urine; interstitial nephritis.
Jaundice; liver enzyme abnormalities.
Thrombocytopenia; megaloblastic anemia.
Hyponatremia; hyperchloremic metabolic acidosis; hyperkalemia.
Anaphylaxis; muscle cramps.
Category B .
Use drug with caution; monitor renal function.
Adult-onset diabetes mellitus
Blood glucose levels may be increased; dosage adjustments of hypoglycemic agents may be needed.
Concurrent diuretic therapy
Dosage reduction may be necessary.
Electrolyte imbalances and BUN increase
Hyperkalemia (serum potassium greater than 5.5 mEq/L), hyponatremia, hyperchloremia, and increases in BUN may occur. Monitor serum electrolytes and BUN levels.
Triamterene is weak folic acid antagonist and may contribute to appearance of megaloblastosis.
May decrease alkali reserve with possibility of metabolic acidosis.
Triamterene has been found in renal stones. Use drug with caution in patients with history of stone formation.
Hypotension, hyperkalemia, metabolic acidosis, nausea, vomiting, weakness, acute renal failure.
- Tell patient to avoid salt substitutes and limit potassium-rich foods.
- Inform patients taking antihypertensives that additive effects are possible; identify signs and symptoms of hypotension and precautions to be taken.
- Advise patient that medication may cause urine to become blue tinged.
- Explain potential GI adverse reactions and to take medication after meals.
- Tell patient that drug may cause weakness, headache, nausea, vomiting, or dry mouth and to notify health care provider if they become severe or persistent.
- Instruct patient to report these symptoms to health care provider: fever, sore throat, mouth sores, unusual bleeding or bruising.
- Caution patient to avoid intake of alcoholic beverages or other CNS depressants.
- Advise patient to use caution while driving or performing other tasks requiring mental alertness.
- Caution patient to avoid exposure to sunlight or ultraviolet light and to use sunscreen or wear protective clothing to prevent photosensitivity reaction.
Copyright © 2009 Wolters Kluwer Health.